Transcatheter aortic valve replacement (TAVR) device, the company's lead product, has been facing rising competition from Abbott, Boston Scientific and Medtronic. The device is used to perform minimally invasive surgery for people with heart valve disease. Edwards on Thursday forecast 2024 TAVR sales in the range of $4.0 billion to $4.3 billion, compared with analysts' estimate of $4.23 billion.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles